Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

Launched by ALZHEIMER'S DISEASE AND RELATED DISORDERS ASSOCIATION, INC · Dec 5, 2023

Keywords

ClinConnect Summary

The Alzheimer's National Registry for Treatment and Diagnostics (ALZ-NET) is a study designed to gather important information about the long-term effects of new FDA-approved treatments for Alzheimer's disease. By observing patients who are either being assessed for these treatments or are already receiving them, ALZ-NET aims to understand how these therapies work in real-life situations. This registry will continue to grow as new treatments become available, allowing researchers and doctors to share vital information that can improve care for Alzheimer's patients.

To participate in this study, individuals must be at least 18 years old and have a diagnosis of mild cognitive impairment (MCI) or dementia, with a suspicion that Alzheimer's disease is involved. They should also be in the process of starting or currently receiving one of the new treatments. Patients or their authorized representatives need to understand the study's purpose and risks, and agree to participate by signing a consent form. Throughout the study, trained medical staff will collect data to ensure everything is done correctly and safely. This important work will help advance our understanding of Alzheimer's treatments and enhance patient care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
• • Patient is at least 18 years of age at the time of informed consent.
• • Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as contributing pathology and (1) is being evaluated for treatment or, (2) will be initiating treatment, or (3) has already initiated treatment with novel FDA-approved AD therapies in real-world clinical practice.
• • If treatment is initiated at the time of consent, patient meets appropriate label requirements and treatment follows appropriate use recommendations for novel FDA-approved AD therapy/therapies.
• • Patient's treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET.